News
-
-
-
-
-
-
PRESS RELEASE
Xenetic Biosciences, Inc. Presents Positive Data Demonstrating DNase I Significantly Improves Efficacy of Anti-CTLA-4 Immune Checkpoint Blockade in Preclinical Colorectal Carcinoma Models
Positive preclinical data on systemic DNase I combined with CTLA-4 antibody presented at SITC 2024, targeting NETs to enhance antitumor immunity and generate immunological memory in MSS/MMRp CRC tumors -
-
-
PRESS RELEASE
Xenetic Biosciences, Inc. Extends Research and Development Collaboration with The Scripps Research Institute to Advance DNase Platform
Xenetic Biosciences extends Research Funding and Option Agreement with The Scripps Research Institute to advance DNase-based oncology program, targeting cancer with NETs via systemic DNase and CAR T-cell therapies -
